These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

609 related articles for article (PubMed ID: 33130203)

  • 1. Role of favipiravir in the treatment of COVID-19.
    Joshi S; Parkar J; Ansari A; Vora A; Talwar D; Tiwaskar M; Patil S; Barkate H
    Int J Infect Dis; 2021 Jan; 102():501-508. PubMed ID: 33130203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early antiviral treatment in outpatients with COVID-19 (FLARE): a structured summary of a study protocol for a randomised controlled trial.
    Brown LK; Freemantle N; Breuer J; Dehbi HM; Chowdhury K; Jones G; Ikeji F; Ndoutoumou A; Santhirakumar K; Longley N; Checkley AM; Standing JF; Lowe DM
    Trials; 2021 Mar; 22(1):193. PubMed ID: 33685502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial.
    Hassaniazad M; Bazram A; Hassanipour S; Fathalipour M
    Trials; 2020 Oct; 21(1):886. PubMed ID: 33109246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Hanna CR; Blyth KG; Burley G; Carmichael S; Evans C; Hinsley S; Khadra I; Khoo S; Lewsley LA; Jones RR; Sharma R; Taladriz-Sender A; Thomson EC; Scott JT
    Trials; 2020 Nov; 21(1):935. PubMed ID: 33213530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19.
    Doi Y; Hibino M; Hase R; Yamamoto M; Kasamatsu Y; Hirose M; Mutoh Y; Homma Y; Terada M; Ogawa T; Kashizaki F; Yokoyama T; Koba H; Kasahara H; Yokota K; Kato H; Yoshida J; Kita T; Kato Y; Kamio T; Kodama N; Uchida Y; Ikeda N; Shinoda M; Nakagawa A; Nakatsumi H; Horiguchi T; Iwata M; Matsuyama A; Banno S; Koseki T; Teramachi M; Miyata M; Tajima S; Maeki T; Nakayama E; Taniguchi S; Lim CK; Saijo M; Imai T; Yoshida H; Kabata D; Shintani A; Yuzawa Y; Kondo M
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The comparison of favipiravir and lopinavir/ritonavir combination in COVID-19 treatment.
    Çınarka H; Günlüoğlu G; Çörtük M; Yurt S; Kıyık M; Koşar F; Tanrıverdi E; Arslan MA; Baydili KN; Koç AS; Altın S; Çetinkaya E
    Turk J Med Sci; 2021 Aug; 51(4):1624-1630. PubMed ID: 33726482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial.
    Lou Y; Liu L; Yao H; Hu X; Su J; Xu K; Luo R; Yang X; He L; Lu X; Zhao Q; Liang T; Qiu Y
    Eur J Pharm Sci; 2021 Feb; 157():105631. PubMed ID: 33115675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favipiravir-induced fever in coronavirus disease 2019: A report of two cases.
    Takoi H; Togashi Y; Fujimori D; Kaizuka H; Otsuki S; Wada T; Takeuchi Y; Abe S
    Int J Infect Dis; 2020 Dec; 101():188-190. PubMed ID: 32992014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
    Kundu S; Sarkar D
    Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favipiravir and COVID-19: A Simplified Summary.
    Ghasemnejad-Berenji M; Pashapour S
    Drug Res (Stuttg); 2021 Mar; 71(3):166-170. PubMed ID: 33176367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
    Solaymani-Dodaran M; Ghanei M; Bagheri M; Qazvini A; Vahedi E; Hassan Saadat S; Amin Setarehdan S; Ansarifar A; Biganeh H; Mohazzab A; Khalili D; Hosein Ghazale A; Reza Heidari M; Taheri A; Khoramdad M; Mahdi Asadi M; Nazemieh M; Varshochi M; Abbasian S; Bakhtiari A; Mosaed R; Hosseini-Shokouh SJ; Shahrokhi M; Yassin Z; Ali Zohal M; Qaraati M; Rastgoo N; Sami R; Javad Eslami M; Asghari A; Namazi M; Ziaie S; Jafari-Moghaddam R; Kalantari S; Memarian M; Khodadadi J; Hossein Afshari M; Momen-Heravi M; Behzadseresht N; Reza Mobayen A; Mozafari A; Movasaghi F; Haddadzadeh Shoushtari M; Moazen J
    Int Immunopharmacol; 2021 Jun; 95():107522. PubMed ID: 33735712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Observational study of the effects of Favipiravir vs Lopinavir/Ritonavir on clinical outcomes in critically Ill patients with COVID-19.
    Kocayiğit H; Özmen Süner K; Tomak Y; Demir G; Yaylacı S; Dheir H; Güçlü E; Erdem AF
    J Clin Pharm Ther; 2021 Apr; 46(2):454-459. PubMed ID: 33128482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.
    Bosaeed M; Mahmoud E; Hussein M; Alharbi A; Alsaedy A; Alothman A; Aljeraisy M; Alqahtani H; Nashabat M; Almutairi B; Almaghaslah M; Aldibasi O; AlJohani S; Bouchama A; Arabi Y; Alaskar A
    Trials; 2020 Oct; 21(1):904. PubMed ID: 33129363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of favipiravir in COVID-19: a live systematic review.
    Özlüşen B; Kozan Ş; Akcan RE; Kalender M; Yaprak D; Peltek İB; Keske Ş; Gönen M; Ergönül Ö
    Eur J Clin Microbiol Infect Dis; 2021 Dec; 40(12):2575-2583. PubMed ID: 34347191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.
    Du YX; Chen XP
    Clin Pharmacol Ther; 2020 Aug; 108(2):242-247. PubMed ID: 32246834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favipiravir in the treatment of patients with SARS-CoV-2 RNA recurrent positive after discharge: A multicenter, open-label, randomized trial.
    Zhao H; Zhang C; Zhu Q; Chen X; Chen G; Sun W; Xiao Z; Du W; Yao J; Li G; Ji Y; Li N; Jiang Y; Wang Y; Zeng Q; Li W; Gong B; Chang X; Zhu F; Jiang X; Li J; Wu Z; Liu Y; Peng P; Wang G
    Int Immunopharmacol; 2021 Aug; 97():107702. PubMed ID: 33930706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic Review on Repurposing Use of Favipiravir Against SARS-CoV-2.
    Nasir M; Perveen RA; Saha SK; Talha KA; Selina F; Islam MA
    Mymensingh Med J; 2020 Jul; 29(3):747-754. PubMed ID: 32844821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favipiravir for treating patients with novel coronavirus (COVID-19): protocol for a systematic review and meta-analysis of randomised clinical trials.
    Arab-Zozani M; Hassanipour S; Ghoddoosi-Nejad D
    BMJ Open; 2020 Jul; 10(7):e039730. PubMed ID: 32737100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.